Injective (INJ) Price Surges Over 900% in 2023
The price of the cryptocurrency Injective (INJ) has experienced a remarkable increase, surpassing 900% since the beginning of the year. This surge has occurred despite a general downward trend in the crypto market. Unlike other blockchains, Injective focuses solely on the financial industry, providing developers with tools to build various financial dApps. It has gained support from billionaire Mark Cuban and is currently ranked 44th based on market capitalization.
Injective Nears Historical Peak with Strong Partnerships
Injective, an interoperable Layer-1 blockchain, is approaching its historical peak value of $31.40, making it one of the top-performing cryptocurrencies this year. It has formed partnerships with Google and Helix exchange to strengthen its position in the market. The integration of “Injective Nexus” with Google Cloud allows mainstream users to access core chain data through the Analytics Hub in BigQuery.
Nexus Integration With Google Cloud Expands Accessibility For Users
Injective’s integration with Google Cloud enables users to access core chain data through the Analytics Hub in BigQuery. This development signifies a major milestone for Injective, as it joins prominent Layer-1 chains like Bitcoin and Ethereum in offering BigQuery datasets on Google Cloud. The bullish trend in INJ’s price is supported by golden confluence in Exponential Moving Averages (EMAs) and a bullish crossover of MACD lines on the daily chart.
Hot Take: Injective Gains Momentum Despite Market Trends
Despite a general downturn in the cryptocurrency market, Injective (INJ) has experienced significant growth and reached a trading value of $13.15. Its partnerships with Google and Helix exchange, along with its focus on the financial industry, have contributed to its success. The integration of “Injective Nexus” with Google Cloud further expands accessibility for users. With its impressive performance and strong partnerships, Injective is positioned for continued growth in the future.
By
By
By
By